Gram-negative Septicemia after Infliximab Treatment in an Infant with Refractory Kawasaki Disease
![]() |
Lee, Jin Hwan
(Department of Pediatrics, Konyang University College of Medicine)
Yoon, Jung Min (Department of Pediatrics, Konyang University College of Medicine) Lim, Jae Woo (Department of Pediatrics, Konyang University College of Medicine) Ko, Kyong Og (Department of Pediatrics, Konyang University College of Medicine) Cheon, Eun Jung (Department of Pediatrics, Konyang University College of Medicine) |
1 | Sundel RP, Burns JC, Baker A, Beiser AS, Newburger JW. Gamma globulin re-treatmetn in Kawasaki disease. J Pediatr 1993;123:657-9. DOI ScienceOn |
2 | Newburger JW, Takahashi M, Burns JC, Beiser AS, Chung KJ, Duffy CE, et al. The treatment of Kawasaki syndrome with intravenous gamma globulin. N Engl J Med 1986;315:341-7. DOI ScienceOn |
3 | Burns JC, Capparelli EV, Brown JA, Newburger JW, Glode MP. Intravenous gamma-globulin treatment and retreatment in Kawasaki disease. US/Canadian Kawasaki Syndrome Study Group. Pediatr Infect Dis J 1998;17:1144-8. DOI ScienceOn |
4 | Melish ME. Kawasaki syndrome. Pediatr Rev 1996;17:153-62. DOI ScienceOn |
5 | Furukawa T, Kishiro M, Akimoto K, Nagata S, Shimizu T, Yamashiro Y. Effects of steroid pulse therapy on immunoglobulin- resistant Kawasaki disease. Arch Dis Child 2008;93:142-6. DOI ScienceOn |
6 | Burns JC, Mason WH, Hauger SB, Janai H, Bastian JF, Wohrley JD, et al. Infliximab treatment for refractory Kawasaki syndrome. J Pediatr 2005;146:662-7. DOI ScienceOn |
7 | Bongartz T, Sutton AJ, Sweeting MJ, Buchan I, Matteson EL, Montori V. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful eff ects in randomized controlled trials. JAMA 2006;295:2275-85. DOI ScienceOn |
8 | Yu HJ, Lee SJ, Sohn S. Infliximab treatment for a patient with refractory Kawasaki disease. Korean J Pediatr 2006;49:987-90. 과학기술학회마을 DOI |
9 | Adriana H, Tremoulet, Sonia J. Infliximab for intensification of primary therapy for Kawasaki disease: a phase 3 randomised, double-blind, placebo-controlled trial. The Lancet 2014;83:1731-8. |
10 | Shin JI, Lee JS, Choi JY, Kim DS, Girish M, Subramaniam. Refractory Kawasaki disease: infliximab or methotrexate therapy? Indian J Pediatr 2009;76:1184. DOI |
11 | Mori M, Imagawa T, Hara R, Kikuchi M, Hara T, Nozawa T, et al. Efficacy and limitation of infliximab treatment for children with Kawasaki disease intractable to intravenous immunoglobulin therapy: report of an open-label case series. J Rheumatol 2012;39:864-7. DOI |
12 | Parashette KR, Makam RC, Cuffari C. Infliximab therapy in pediatric Crohn's disease: a review. Clin Exp Gastroenterol 2010;3:57-63. DOI |
13 | Matsubara T, Furukawa S, Yabuta K. Serum levels of tumor necrosis factor, interleukin 2 receptor, and interferon-gamma in Kawasaki disease involved coronary-artery lesions. Clin Immunol Immunopathol 1990;56:29-36. DOI ScienceOn |
14 | Burns JC, Best BM, Mejias A, Mahony L, Fixler DE, Jafri HS, et al. Infliximab treatment of intravenous immunoglobulin-resistant Kawasaki disease J Pediatr 2008;153:833-8. DOI |
15 | Maini RN, Taylor PC. Anti-cytokine therapy for rheumatoid arthritis. Annu Rev Med 2000;51:207-29. DOI |
16 | Stratakos G, Kalomenidis I, Papas V, Malagari K, Kollintza A, Roussos C, et al. Cough and fever in a female with Crohn's disease receiving infliximab. Eur Respir J 2005;26:354-7. DOI |
17 | Miyamoto H, Miura T, Morita E, Morizaki Y, Uehara K, Ohe T, et al. Fungal arthritis of the wrist caused by Candida parapsilosis during infliximab therapy for rheumatoid arthritis. Mod Rheumatol 2012;22:903-6. DOI |
18 | Keane J, Gershon S, Wise RP, Mirabile-Levens E, Kasznica J, Schwieterman WD, et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 2001;345:1098-104. DOI ScienceOn |
19 | Kroesen S, Widmer AF, Tyndall A, Hasler P. Serious bacterial infections in patients with rheumatoid arthritis under anti-TNF-alpha therapy. Rheumatology (Oxford) 2003;42:617-21. DOI |
20 | Leung DY, Meissner C, Fulton D, Schlievert PM. The potential role of bacterial superantigens in the pathogenesis of Kawasaki syndrome. J Clin Immunol 1995;15:11S-7S. DOI |
21 | Bergogne BE, Towner K. Acinetobacter spp. as nosocomial pathogens: Microbiological, clinical, and epidemiologic features. Clin Microbiol Rev 1996;9:148-65. |
22 | Bruns H, Meinken C, Schauenberg P, Harter G, Kern P, Modlin RL, et al. Anti-TNF immunotherapy reduces CD8+ T cell-mediated antimicrobial activity against Mycobacterium tuberculosis in humans. J Clin Invest 2009;119:1167-77. DOI |
![]() |